---
document_datetime: 2023-09-21 18:40:21
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/paxene-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: paxene-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.5824106
conversion_datetime: 2025-12-30 08:51:07.016432
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Paxene

## Procedural steps taken and scientific information after the authorisation

## Changes made after 30/11/2004

## For procedures finalised before 30/11/2004, please refer to module 8A

## MAJOR CHANGES 1

<!-- image -->

| No      | Scope                                                            | Opinion issued on    | Commission Decision Issued/ amended on   | Product Information affected 2      | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------|------------------------------------------------------------------|----------------------|------------------------------------------|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0047  | Renewal of the Marketing Authorisation                           | 23/04/2009           | 14/07/2009                               | SPC, Annex II, Labelling, PL longer | Based on the CHMP review of the available information and on the basis of the re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Paxene continues to be favourable. The CHMP is also of the opinion that the renewal can be granted with unlimited validity. PSURs will now be submitted every 3 years. authorised                          |
| II/0042 | Update of Summary of Product Characteristics and Package Leaflet | 24/04/2008           | 19/06/2008 product                       | SPC, PL no                          | This type II variation concerns an update of section 4.5 of the SPC, upon request by CHMP following the assessment of the 10th PSUR, to add information about an interaction with doxorubicin. The Package Leaflet has been revised accordingly. In addition, the MAHtook the opportunity to implement some minor editorial changes in the SPC. Since elimination of doxorubicin and its active metabolites may be reduced when paclitaxel and doxorubicin are used in combination, paclitaxel should be administered 24 hours after doxorubicin. |
| II/0037 | Quality changes                                                  | 26/04/2007 Medicinal | 07/05/2007                               |                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0035 | Update of Summary of Product Characteristics and Package Leaflet | 16/11/2006           | 24/01/2007                               | SPC, PL                             | The Marketing Authorisation Holder applied for a type II variation, upon request by the CHMP following the assessment of the 8th and 9th PSURs, to add the ADR \"lung fibrosis\" to section 4.8 of the SPC. The Package Leaflet has been updated accordingly. In addition, the Marketing Authorisation Holder took the opportunity to update the list of local representatives in the Package Leaflet with the contact details                                                                                                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No      | Scope                                                            | Opinion issued on    | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|------------------------------------------------------------------|----------------------|------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |                                                                  |                      |                                          |                                  | for Bulgaria and Romania.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0034 | Update of Summary of Product Characteristics and Package Leaflet | 15/09/2005           | 25/10/2005 product                       | SPC, PL no longer                | The MAHapplied, following a request from CHMP, for a variation to harmonise sections 4.2, 4.4 and 4.5 of the SPC and corresponding sections of the PL with that of Taxol (paclitaxel). With reference to sections 4.2 and 4.4, it has been highlighted that patients with hepatic impairment may be at increased risk of toxicity, particularly Grade 3-4 myelosuppression. There is no evidence that the toxicity of paclitaxel is increased when given as a 3-hour infusion to patients with mildly abnormal liver function. When given as a longer infusion, increased myelosuppression may be seen in patients with moderate to severe hepatic impairment. Patients should be closely monitored for the development of profound myelosuppression. Adequate data are not available to recommend dosage alterations in patients with mild to moderate hepatic impairments. No data are available for patients with severe baseline cholestasis. Patients with severe hepatic impairment should not be treated with paclitaxel. With reference to section 4.5, gemfibrozil has been added to the list of drugs known to inhibit cytochrome P450 isoenzymes CYP 3A4 and 2C8 and phenobarbital to the list of drugs known to induce these enzymes. Further, it is now highlighted that concurrent administration of ketoconazole, a known potent inhibitor of CYP3A4, does not inhibit the elimination of paclitaxel in patients; thus, both medicinal products may be administered together without dosage adjustment. Further data on the potential of drug interactions between paclitaxel and other CYP3A4 substrates/inhibitors are limited. authorised |
| II/0032 | Change in or addition of manufacturer(s) of active substance     | 27/07/2005 Medicinal | 08/08/2005                               |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0026 | Extension of Indication                                          | 17/02/2005           | 20/04/2005                               | SPC, PL                          | The MAHapplied for an extension of indication for the treatment of patients with non-small cell lung carcinoma (NSCLC) who are not candidates for potentially curative surgery and/or radiation therapy, in combination with cisplatin as first-line treatment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0025 | Extension of Indication                                          | 17/02/2005           | 20/04/2005                               | SPC, PL                          | The MAHapplied for an extension of indication for the treatment of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| No      | Scope           | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                |
|---------|-----------------|---------------------|------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |                 |                     |                                          |                                  | patients with advanced carcinoma of the ovary (AOC) or with residual disease (> 1 cm) after initial laparotomy, in combination with cisplatin as first-line treatment. |
| II/0024 | Quality changes | 15/12/2004          | 03/01/2005                               |                                  |                                                                                                                                                                        |
| II/0031 | Quality changes | 15/12/2004          | 20/12/2004                               |                                  |                                                                                                                                                                        |

## MINOR CHANGES 3

| No      | Scope                                                                                                  | Product Information affected 2   | Date 4     |
|---------|--------------------------------------------------------------------------------------------------------|----------------------------------|------------|
| IA/0049 | 04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) longer |                                  | 04/03/2009 |
| IA/0046 | 08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing no           | Annex II, PL                     | 11/03/2008 |
| IA/0045 | 09_Deletion of manufacturing site                                                                      | Annex II                         | 11/03/2008 |
| IA/0044 | 09_Deletion of manufacturing site                                                                      | Annex II                         | 11/03/2008 |
| IA/0039 | 05_Change in the name and/or address of a manufacturer of the finished product                         |                                  | 18/12/2007 |
| N/0038  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)       | PL                               | 03/05/2007 |
| IB/0028 | 42_a_02_Change in shelf-life of finished product - after first opening                                 | SPC, Labelling, PL               | 20/12/2004 |

Medicinal product no longer authorised

3 Minor changes e.g. Type I variations and Notifications

4 Date of entry into force of the change